UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 28, 2007

CryoCor, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-51410

33-0922667

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

9717 Pacific Heights Boulevard

San Diego, California

92121

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (858) 909-2200

Not Applicable.

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

On June 28, 2007, the Compensation Committee of our Board of Directors (the “Compensation Committee”) approved revisions to certain corporate goals for 2007 in connection with the annual bonus for Dr. Helen S. Barold, our Chief Medical Officer. Subsequently, on July 3, 2007, the Compensation Committee superseded the above referenced approval and approved a bonus award of $100,000 to be paid to Dr. Barold in recognition of her work on our behalf in connection with the U.S. Food and Drug Administration’s (“FDA”) Advisory Panel meeting held on June 27, 2007 and the FDA’s review of our application for pre-market approval relating to the treatment of atrial flutter.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


				CryoCor, Inc.

				By:		/s/ Gregory J. Tibbitts
						Gregory J. Tibbitts
						Vice President, Finance and Chief Financial Officer
						(Principal Financial and Accounting Officer)

Date: July 5, 2007

CRYOCOR INC 8-K